Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 55

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 55
---
 West 33rd Street, Suite 1910, New York, NY 10120. (3) With respect to entities affiliated with Longitude Venture Partners II, L.P. (“LVPII”), we have relied solely on information supplied by such entity on a Schedule 13G filed with the SEC on February 14, 2023. Consists of (i) 3,407,952 shares of Class A common stock held by LVPII, (ii) 150,000 shares of Class A common stock held by Longitude Prime Fund, L.P. (“LPF” and together with LVPII, the “Longitude Entities”) and (iii) 631,893 shares of Class A common stock issuable upon the conversion of warrants exercisable within 60 days of March 10, 2023 held by LVPII. Longitude Capital Partners II, LLC (“LCPII”) is the general partner of LVPII and may be deemed to have voting and investment power over the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCPII and may be deemed to share voting and investment power over the shares held by LVPII. As general partner of LPF, Longitude Prime Partners, LLC (“LPP”) may be deemed to beneficially own the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power with respect to the shares held by LPF. LCPII, LPP, Mr. Enright, and Ms. Tammenoms Bakker each disclaim beneficial 37

#### TABLE OF CONTENTS
ownership of such shares except to the extent of their respective pecuniary interest therein. The mailing address for each of the entities and individuals above is 2740 Sand Hill Road, Menlo Park, California 94025.

(4) With respect to entities affiliated with Endeavour Medtech Growth II LP (“Endeavour Growth”), we have relied solely on information supplied by such entities on a Schedule 13G/A filed with the SEC on January 22, 2024. Consists of (i) 2,217,190 shares of Class A common stock held by Endeavour Growth, and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth Parallel II LP (“Endeavour Parallel”). The general partner of Endeavour Growth